In 2026, Medicare will introduce pivotal changes to the coverage of diabetes monitors, impacting continuous glucose monitors and insulin pumps. These adjustments, part of the new Home Health Rule, will alter preferred brands and eligibility criteria, raising concerns about access and affordability. Explore how these developments will affect patients and providers in the evolving landscape of diabetes care.
Understanding Medicare Coverage for Diabetes Monitors in 2026
As the landscape of healthcare continues to evolve, significant changes are on the horizon for Medicare coverage of diabetes monitors. Starting in 2026, Medicare will implement new rules affecting the coverage of continuous glucose monitors (CGMs) and insulin pumps for beneficiaries with diabetes. These changes are part of the final 2026 Home Health Rule released by the Centers for Medicare & Medicaid Services (CMS), which has raised concerns about potential limitations in access to these essential devices (source).
Changes in Preferred Brands and Coverage
One of the notable changes involves the shift in preferred brands for diabetic test strips under Medicare Advantage plans. Effective January 1, 2026, Independence Blue Cross Medicare Advantage plans will no longer cover OneTouch diabetic test strips at the preferred cost-sharing level. Instead, Accu-Chek and Contour will become the only preferred brands. Providers are advised to switch patients to Accu-Chek test strips immediately to avoid disruptions in care, while the transition to Contour test strips should occur starting in 2026 (source).
Eligibility and Coverage Criteria for CGMs
Medicare may cover continuous glucose monitors and related supplies for eligible individuals with diabetes. To qualify, a patient must have diabetes, be prescribed the device by a healthcare provider, and have received adequate training to use the monitor. The healthcare provider must evaluate the patient’s condition to determine eligibility. Coverage is contingent upon a prescription and meeting specific conditions, such as taking insulin or having a history of hypoglycemia (source).
Impact on Patients and Providers
The changes in Medicare coverage for diabetes monitors will have a significant impact on both patients and healthcare providers. The American Diabetes Association (ADA) has been actively engaging with policymakers to emphasize the importance of maintaining patient and provider choice in selecting CGMs and insulin pumps. The ADA advocates for individualized device selection based on a patient’s specific needs, circumstances, preferences, and skill level. They are urging CMS to collaborate with the diabetes community to prevent any gaps in access, coverage, or affordability for Medicare beneficiaries as the new rule is implemented (source).
Cost Considerations and Supplier Requirements
After meeting the Part B deductible, patients are responsible for 20% of the Medicare-approved amount if the supplier accepts assignment. Non-participating suppliers may charge more, and patients may need to pay the full cost upfront if claims are not assigned. It is crucial for both healthcare providers and DME suppliers to be enrolled in Medicare. Patients should confirm that suppliers participate in Medicare and accept assignment of claims to avoid additional costs (source).
Why You Should Learn More About Medicare Coverage for Diabetes Monitors Today
Understanding the upcoming changes in Medicare coverage for diabetes monitors is crucial for both patients and healthcare providers. With significant shifts in preferred brands and coverage criteria, staying informed can help ensure continuous access to essential diabetes management devices. The American Diabetes Association’s advocacy efforts highlight the importance of maintaining patient and provider choice in selecting the most suitable devices. As the 2026 Home Health Rule approaches, it is vital to be aware of the potential impacts on access, coverage, and affordability. By staying informed, patients and providers can better navigate the evolving landscape of diabetes care under Medicare.